ETX-101- Diabetic Gastroparesis
ETX-101 is the only drug currently in development that treats the underlying disease process and should enjoy rapid adoption in this underserved indication
ETX-202 - IBD - Crohn's Disease
ETX-202 treats the underlying disease process for IBD-CD and IBD-UC (Crohn's Disease and Ulcerative Colitis) and is known safe and administered orally.
ETX pre-clinical compound (ETX-301) is in development for severe gastroparesis where the disease is at the end-stage
ETX has a balanced Pipeline of drugs providing sustained shareholder value and multiple exit opportunities as well as a clear executable development plan. For more information please click here Pipeline.
Please contact ETX Pharma, Inc for more information.